How to reimburse Dasatinib imported drug

Dasatinib (Dasatinib), as an important targeted therapy drug, has been approved for marketing in China and has been included in the scope of medical insurance reimbursement. However, the conditions for patients to obtain reimbursement when using dasatinib are very strict. These conditions mainly include the patient's diagnosis, treatment stage, and previous treatment experience.

Patients must be diagnosed with Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML) or acute lymphoblastic leukemia (ALL). Specifically, only those newly diagnosed patients with chronic phase CML, or those who are resistant or intolerant to other drugs such as imatinib during treatment, can enjoy the relevant reimbursement policies of medical insurance. In addition, this type of reimbursement policy also applies to pediatric patients, but they also need to meet certain diagnostic conditions.

Patients usually need to provide multiple supporting documents when applying for reimbursement. This includes but is not limited to the doctor's diagnosis certificate, medical records, treatment plans, medication records, etc. Hospitals usually require patients to submit reimbursement applications to a dedicated pharmacy department for review. Patients need to ensure that the materials submitted are complete and accurate to avoid rejection of reimbursement applications due to incomplete materials.

There are two main ways to obtain dasatinib: directly through the hospital’s pharmacy, or through a drug distribution company that cooperates with medical institutions. In terms of cost, although dasatinib has been included in medical insurance, the reimbursement ratio may vary from region to region, and in most cases only covers part of the cost of the drug. Therefore, patients still have to bear certain costs. After confirming the reimbursement ratio, patients need to understand the personal expenses borne by the medical insurance in order to reasonably arrange their financial expenditures.